Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share allocation prices and quantities for directors.
- Ordinary Share Allocation Price: £12.51 per share
- ADS Allocation Price: $37.86 per ADS
- Service Period Covered: July 1, 2015, to September 30, 2015
Material Changes
The filing reports the allocation of notional Ordinary Shares and American Depositary Shares (ADSs) to Non-Executive Directors on September 30, 2015. No comparative financial data or material changes in operational metrics are provided in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors to Verify
- Verify the total number of notional shares allocated to each Non-Executive Director listed (e.g., Sir Philip Hampton: 3,497.202 shares; Lynn Elsenhans: 1,552.170 shares).
- Confirm the allocation prices of £12.51 per Ordinary Share and $37.86 per ADS against market prices on September 30, 2015.
- Review the full list of Non-Executive Directors to ensure all allocations are accounted for in the company's internal records.